The activation of innate and adaptive immunity via Stimulator of Interferon Genes (STING) signaling is a potentially transformative immuno-therapeutic strategy in cancer. We report here the in vivo efficacy and safety studies of SB 11285.
Background:
The activation of innate and adaptive immunity via Stimulator of Interferon Genes (STING) signaling is a potentially transformative immuno-therapeutic strategy in cancer. We report here the in vivo efficacy and safety studies of SB 11285. Table. (2) Re-challenge study was initiated in tumor-free animals in A20 lymphoma model on day 73, and monitored for an additional 45 days. Table 1 shows MTV on day 19 and %TGD on day 43; (iii) Re-challenge study. All animals from the SB 11285-treated groups remained completely tumor-free on day 45 compared to control group (MTV,1666 mm 3 ); (iv) Immuno-histochemistry of SB 11285-treated groups, revealed the infiltration of CD8 + T and NK cells into tumor and surrounding tissues; (v) Cytokine analysis did not show systemic inflammatory response; (vi) MTD of i.p. SB 11285 was 16 mg/kg/day. . Conclusion: SB 11285, a novel STING agonist, showed very potent, and highly durable immune response-mediated anti-tumor activity. SB 11285 was well tolerated, safe, and is being advanced to IND-enabling studies. 
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